Sensus Healthcare (NASDAQ:SRTS) Director Eric Sachetta Acquires 37,537 Shares of Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta bought 37,537 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were purchased at an average cost of $3.44 per share, with a total value of $129,127.28. Following the purchase, the director directly owned 267,480 shares of the company’s stock, valued at $920,131.20. The trade was a 16.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Eric Sachetta also recently made the following trade(s):

• On Monday, August 31st, Eric Sachetta bought 27,304 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.54 per share, for a total transaction of $96,656.16.
• On Thursday, August 27th, Eric Sachetta purchased 10,925 shares of Sensus Healthcare stock. The shares were purchased at an average cost of $3.18 per share, for a total transaction of $34,741.50.
• On Wednesday, August 26th, Eric Sachetta purchased 9,708 shares of Sensus Healthcare stock. The shares were acquired at an average price of $3.29 per share, with a total value of $31,939.32.
• On Monday, August 24th, Eric Sachetta acquired 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Trading Up 0.6%

SRTS stock opened at $3.54 on Tuesday. The firm has a market cap of $58.27 million, a PE ratio of -3.77 and a beta of 1.10. The stock has a 50-day moving average price of $3.07 and a 200-day moving average price of $3.51. Sensus Healthcare, Inc. has a 1-year low of $2.66 and a 1-year high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $4.60 million.

Wall Street Analyst Weigh In

Several analysts have recently commented on SRTS shares. Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Lake Street Capital dropped their target price on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Weiss Ratings cut shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.83.

Hedge Funds Weigh In On Sensus Healthcare

Institutional investors have recently modified their holdings of the company. EP Wealth Advisors LLC bought a new position in shares of Sensus Healthcare in the 2nd quarter worth $49,000. XTX Topco Ltd bought a new position in shares of Sensus Healthcare in the fourth quarter valued at $77,000. Jane Street Group LLC acquired a new position in shares of Sensus Healthcare during the fourth quarter valued at about $79,000. Ingalls & Snyder LLC bought a new stake in shares of Sensus Healthcare during the fourth quarter worth about $219,000. Finally, State Street Corp raised its holdings in shares of Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after acquiring an additional 3,400 shares during the last quarter. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.